BioSpace looks at some of the top stories from Day 2 of the virtual JP Morgan Annual Healthcare Conference.
Despite some controversy over the effectiveness of Gilead Sciences’ Veklury (remdesivir), the product is bolstering the company’s bottom line.
Antiviral protein MDA-5 senses viral replication and governs immune response to SARS-CoV-2 Credit: Sanford Burnham Prebys Medical Discovery Institute LA JOLLA, CALIF. – Jan 12, 2020...
COVID-19 & The Emergence Of The Pandemic Industrial Complex Authored by Brian Berletic via ActivistPost.com, If official numbers are to be believed, the United States is...
Gilead Sciences raised its full-year 2020 profit forecast on Monday fueled by demand for its remdesivir treatment during the COVID-19 pandemic. Shares rose 1.2% in early...
CNBC Exclusive: CNBC Transcript: Gilead Sciences Chairman & CEO Daniel O’Day speaks with CNBC’s “Squawk Box” today about raising full-year guidance due to remdesivir sales. Q3...
While biopharma was dominated by COVID-19, which prompted a surge of research and business activity, the industry also saw developments that will position it for further...
Treating critically ill Covid-19 patients with Roche’s Actemra or Sanofi’s Kevzara arthritis drugs significantly improves survival rates and reduces the amount of time patients need intensive...
Despite No Lockdown/Mask-Mandate, Florida Has Same Hospitalization Rate As 2018 Flu Season Authored by Daniel Horowitz via TheBlaze.com, The entire pretext for shutting down our liberties...
Review of the life histories of RNA viruses, their genetics, and the compounds that could disrupt them offers hope for curtailment of future pandemics Credit: Illustration:...
The chemotherapy pralatrexate and the antibiotic azithromycin were successful at preventing replication of the SARS-CoV-2 virus, according to research with Shenzhen Institutes of Advanced Technology in...
BioSpace reviewed the top 10 novel drug approvals of 2020, loosely based on projected earnings in the upcoming years.
A new year, a new addition to the stock portfolio – what can make more sense than that? The right time to buy, of course, is...
An unprecedented pandemic did not stop the US stock market from finishing 2020 on a high note. The S&P 500 ended a highly volatile year at...
In lab experiments, pralatrexate outperforms remdesivir against SARS-CoV-2 Credit: National Institute of Allergy and Infectious Diseases/NIH, 2020 (CC0) A novel computational drug screening strategy combined with...
Pharmaceutical scientist sees potential problems with remdesivir as a COVID-19 treatment Credit: University of Cincinnati While the world has its eyes on vaccines to stop the...
These tickers changing hands for less than $5 per share either draw investors in with their high return potential or send them running.
The additional challenges to launching new drugs that emerged since COVID-19 upended the biopharma industry, and life as we knew it, will continue into 2021. Yet...
Experimental monoclonal antibody not efficacious in Phase 3 trial Credit: NIAID Preliminary results of a phase 3, randomized, placebo-controlled clinical trial testing the investigative monoclonal antibody...
As the search for more potential Covid-19 treatments continues, Kiniksa Pharmaceuticals $KNSA has revealed data for a repurposed immunology candidate it says are positive. But the...
A husband-and-wife biotech that flipped a Covid-19 antiviral to Merck earlier this summer has a new approval in another highly infectious disease — Ebola. Wendy Holman...
Two weeks ago, Vicore reported mid-stage data showing that its lead drug C21 could boost the benefit of The post Vicore builds case for C21 drug...
The development of multiple vaccines against the virus that causes COVID-19 has been hailed as the breakthrough of 2020. But there were many more supporting discoveries...
The Austrian researchers are the first in the world to demonstrate ‘YeiN’, an enzyme that is a suitable biocatalyst for the production of C-nucleosides, the basic...
Incyte and Novartis announced a Phase III study of Jakafi (ruxolitinib), a first-in-class JAK1/JAK2 inhibitor, failed to hit endpoints as a treatment for patients 12 and...
A single-patient study conducted by British scientists found that Gilead’s remdesivir could be highly effective against Covid-19, raising questions about previous studies that found the antiviral...
We should applaud drug companies for developing COVID-19 vaccines in record time, but let’s not be under any illusion about the profits that are motivating them.
Novartis/Incyte’s Jakafi (ruxolitinib) looks unlikely to be added to the list of therapies that can be used against The post Novartis/Incyte draw blank with Jakafi in...
Peer-reviewed results of NIH clinical trial published Credit: NIAID WHAT: The combination of baricitinib, an anti-inflammatory drug, and remdesivir, an antiviral, reduced time to recovery for...
Five key genes are linked with the most severe form of Covid-19, scientists said, in research that also pointed to several existing drugs that could be...